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Abstract
Bloodstream infection is associated with signiﬁcant short-term mortality, but less is known about long-term outcome. We describe factors
affecting mortality up to 3 years after bloodstream infection in a cohort of patients reviewed at the bedside by an infection specialist.
Patients seen by the bacteraemia service of our infectious diseases department between June 2005 and November 2008 were included in
analyses. Routine clinical data collected at the time of consultation, together with laboratory, demographic and outcome data were analysed
to identify factors predicting death at 30 days and 3 years after bloodstream infection. Cox regression models for both time-points were
constructed, together with Kaplan–Meier survival curves. In all, 322 bloodstream infections were recorded in 304 patients. The 30-day
mortality was 15%, with a 3-year mortality of 49%. At 30 days after bacteraemia, in the Cox regression model, increasing age (p 0.003) and
lower serum albumin (p 0.014) were predictive of death. At 3 years, age (p <0.0001) and albumin (p 0.004) remained signiﬁcant predictors
of death, with the presence of vascular disease (p 0.05) also signiﬁcantly associated with mortality. If temperature was treated as a
continuous variable then urea was signiﬁcant (p 0.044); however, if temperature was categorized into hypothermia and non-hypothermia,
then the presence of hypothermia (p 0.008) and chronic renal disease (p 0.034) became signiﬁcant. There is an appreciable and gradual
increase in mortality after an episode of bloodstream infection. Although many factors may not be amenable to intervention, patients at high
risk of long-term mortality might require further follow up and assessment for potentially modiﬁable factors.
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Introduction
Bacteraemia (bloodstream infection), whether associated with
another site of infection or not, is a common cause of
community and healthcare-associated infection and causes high
early mortality in the range of 11–30% [1–8]. Most studies
have concentrated on in-hospital or early mortality, few have
looked at longer-term outcomes, particularly beyond 1 year.
One study performed in Israel in the early 1990s showed a 1-
year mortality of 48%, with a 4-year mortality of 63% [1]. A
study from the same period, performed in Boston, USA,
showed a 3-year mortality of 37% [2]. Both of these studies
showed that patients who had had bacteraemia had a higher
mortality than matched control people who had not. The
reason for the apparent excess in longer-term mortality
remains unclear, but possible explanations could be that
bacteraemia is a marker of co-morbidity (e.g. in patients with
renal impairment or malignancy) or it may trigger, for example,
a long-term, low-grade inﬂammatory response, which subse-
quently leads to either destabilization of an existing co-
morbidity or a new one, such as vascular disease. The latter, in
particular, raises the possibility of early medical intervention
following an episode of bacteraemia to reduce long-term
mortality, although this approach is as yet unproven. Given the
changes in patient demographics, co-morbidity and antibiotic
resistance that have occurred over the last 20 years, little is
known of the contemporary long-term mortality after blood-
stream infection. We describe here the factors affecting
mortality up to 3 years after bloodstream infection, in a UK
teaching hospital bacteraemia service cohort.
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Methods
Study population
The bacteraemia service at Hull and East Yorkshire Hospitals
(a 1500-bed, two-site hospital trust, serving a population of
approximately 1.2 million) has been described previously[6].
Brieﬂy, between June 2005 and November 2008, patients with
a presumed infecting pathogen isolated from blood cultures
were reviewed at the bedside by an infectious diseases
physician, either a consultant or a Specialist Trainee (Fellow),
without previous solicitation by the patient’s clinical team.
Patients with haematological malignancy and those with solid
organ tumours who were undergoing chemotherapy, patients
already on the infectious diseases unit and children aged
<16 years were not routinely reviewed because other existing
infection services cover these areas. Initial antibiotic advice
was provided by either a consultant or a Specialist Trainee
(Fellow) in microbiology by telephone, with a structured and
more detailed report provided following a bedside consulta-
tion by a consultant or Specialist Trainee (Fellow) in infectious
diseases (a median of 3 days after blood cultures were taken).
Data collection
Data were recorded or dictated at the time of consultation,
using a structured and pre-piloted, paper-based proforma,
which also formed the report sent to the patient’s clinical team
as part of routine clinical practice. These included demographic
data (gender and age), clinical observations (pulse, temperature,
blood pressure and respiratory rate), relevant examination data
(source of infection), microbiological and antibiotic data. These
data were entered onto an EXCEL spreadsheet to which, via the
hospital computer system, were added standard laboratory
data from the time the blood culture was taken (or within 24 h),
data regarding socio-economic deprivation (postal code of
patient’s address was used to derive the Index of Multiple
Deprivation Score, using UKOfﬁce of National Statistics census
data), co-morbidities and date of death. Data collection and
analysis were approved for ongoing quality improvement,
service evaluation and audit by the Hull and East Yorkshire
Hospitals NHS Trust. No funding was required for this work.
Data analysis
Factors associated with mortality at both 30 days and 3 years
were ascertained. Two separate analyses were performed; one
using patients with a complete data set and subsequent analyses
including patients with missing values, with the missing values
imputed using the expectation-maximization method. Initial
analyses were univariate, using Mann–Whitney and Fisher’s
exact tests as appropriate. Factors signiﬁcant at a level of
p  0.1 in univariate analyses were entered into a Cox
regression model, with backwards removal of variables until
the ﬁnal model was achieved, with co-morbidities being entered
into the models to adjust for them. Kaplan–Meier survival
curves for signiﬁcant predictors of 3-year mortality were
constructed and analysed using the log-rank test. Analyses were
performed using GRAPHPAD PRISM 5 and SPSS (version 19.0).
Results
Patient cohort
Three hundred and twenty-two bacteraemic episodes were
reviewed in 304 separate patients between June 2005 and
November 2008. The median age of patients was 70 years
(interquartile range 57–79) and 60.6% were women. The
organisms isolated are shown in Table 1, with methicillin-
sensitive Staphylococcus aureus, methicillin-resistant S. aureus
and Escherichia coli being the commonest single isolates. Of the
322 patients, 263 (81.6%) were receiving effective antibiotic
therapy, based on antibiotic sensitivity, before being reviewed
by an infectious diseases physician at the bedside, increasing to
292 (90.7%) after review (p <0.0001, McNemar’s test).
However, receipt of ineffective therapy was not associated
with either 30-day (p 0.85) or 3-year (p 0.77) mortality. The
overall mortality is shown in Figure 1, with a 30-day mortality
of 15% and a 3-year mortality of 48.75%.
TABLE 1. Common organisms isolated
Organism Number isolated
Methicillin-sensitive Staphylococccus aureus (MSSA) 94
Methicillin-resistant Staphylococcus aureus (MRSA) 51
Coagulase-negative staphylococci 47
Streptococci 44
Escherichia coli 36
Non-speciﬁed coliform 29
Enterococci 24
Candida spp. 9
Pseudomonas sp. 7
Klebsiella sp 6
Polymicrobial cases 40
FIG. 1. Overall survival.
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Thirty-day mortality
Table 2 shows the univariate and Cox regression predictors of
mortality by 30 days. Both lower serum albumin and increasing
age remained signiﬁcant predictors of mortality in secondary
analyses when missing values were imputed using an
expectation-maximization method (data not shown).
Three-year mortality and survival curves
The complete data set without missing values, was used to
construct a Cox regression model, the results of which are
shown in Table 3. When the data set was expanded to include
missing variables that had been imputed as described previ-
ously, age and albumin remained signiﬁcant predictors of
mortality, with higher respiratory rate (p 0.021, OR 1.033/
breaths/minute), lower body temperature (p 0.045, OR 0.868/
°C increase) and chronic renal disease (p 0.047 OR 0.684 for
absence of renal disease) but creatinine replaced urea as
predictive of mortality (p 0.046, OR 1.001/lmol increase),
with vascular disease becoming non-signiﬁcant. In a second
analysis, where temperature was treated as a binary variable
(hypothermia/non-hypothermia), the presence of hypothermia
was strongly associated with 3-year mortality (p 0.008, OR
2.738), replacing markers of renal dysfunction. Kaplan–Meier
survival curves for quartiles of age, albumin, urea and
temperature are shown in Figure 2.
Discussion
There are relatively few data regarding long-term outcome
after bloodstream infection from the current era. Although
some data from population-based studies are available, the
other commonly cited papers are now nearly 20 years old and
may not reﬂect the increasingly elderly population with high
levels of co-morbidity. Conversely, with improved infection
input and specialist review, it is possible that outcomes may be
relatively improved compared with earlier reports. Of the
factors not associated with mortality in our cohort, perhaps
the most interesting and surprising is the lack of effect of
inappropriate antibiotic therapy. Although this was shown to
inﬂuence long-term mortality in the study from Israel [1], this
may be less evident in our cohort given the large proportion of
patients who received appropriate empirical antibacterial
therapy; we were not able to accurately measure the time
between onset of illness and receipt of empiric or appropriate
antibiotic therapy. Another explanation might be that our
study was not large enough to detect a small, but clinically
relevant difference. The data regarding socio-economic depri-
vation and infection are limited, although our unit recently
found that the incidence of invasive pneumococcal disease was
higher in those with higher Index of Multiple Deprivation
Scores (an index of global deprivation ranked 0–100, with
higher scores indicating greater deprivation) [9]. The data from
this cohort would however seem to suggest that this may not
translate into a poorer outcome when infection occurs.
Our data conﬁrm the effects of age on both short-term and
long-term mortality after bloodstream infection [1–4,8],
together with the known association of low serum albumin
with higher mortality at both time-points [1,10]. Whether the
latter can be modiﬁed by, for example, better management of
existing co-morbidities that cause hypoalbuminaemia or better
nutritional support is debatable, but our results suggest that
physicians should review both of these in the recovery period
after an episode of bacteraemia. Although mortality was
considerably higher in older age quartiles, there was still
notable mortality in the two younger quartiles with a steady
TABLE 2. Predictors of 30-day mortality at the time of bacteraemia
Variable Died by 30 days (n = 61) Survived to 30 days (n = 261) Univariate p value Cox regression p value OR (95% CI)
Age (years)a 77 68 <0.0001 0.003 1.046 (1.016–1.078)
IMDSa 21.8 30.9 >0.1 N/A N/A
MRSA (compared with all
other isolates)
20 (32.8) 31 (11.9) 0.0003 >0.1 N/A
Pulse (/min)a 90 94 >0.1 N/A N/A
Systolic BP (mmHg)a 115 120 >0.1 N/A N/A
Respiratory rate (/min)a 20 19 0.0942 >0.1 N/A
Temperature (°C)a 37.9 38.0 >0.1 N/A N/A
Creatinine (lmol/L)a 144 119 >0.1 N/A N/A
Urea (mmol/L)a 12.5 8.4 0.0011 >0.1 N/A
Haemoglobin (g/dL)a 10.2 10.8 0.0452 >0.1 N/A
White cell count (9109)a 11.9 12 >0.1 N/A N/A
Albumin (g/L)a 22 26 0.0001 0.019 0.928 (0.872–0.988)
CRP (mg/L)a 170.5 165.5 >0.1 N/A N/A
Initial antibiotic active 49 (80.3) 214 (82) >0.1 N/A N/A
Vascular co-morbidity 18 (29.5) 91 (34.9) >0.1 N/A N/A
Renal co-morbidity 16 (26.2) 76 (29.1) >0.1 N/A N/A
Respiratory co-morbidity 4 (6.6) 34 (13) >0.1 N/A N/A
Diabetic 10 (16.4) 55 (21.1) >0.1 N/A N/A
aValues are medians or absolute values (%).
IMDS, Index of Multiple Deprivation Score; MRSA, methicillin-resistant Staphylococcus aureus; BP, blood pressure; CRP, C-reactive protein.
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increase in mortality over the 3-year follow-up period. Our
results point to simple markers of renal function (urea or
creatinine) as being important predictors of longer-term
mortality. Whereas the effect of elevated creatinine has been
noted previously [1], this may be of clinical utility as a target
for intervention. As impaired renal function is an important
marker for cardiovascular disease [11,12], and a recent study
from Canada showed that nearly 25% of deaths in the year
following an episode of bacteraemia were due to vascular
disease [3], it may be that the group of patients with impaired
renal function are at higher risk of dying, possibly as the result
of vascular events. This may also explain one of the reasons for
the mortality beneﬁt detected in patients with bacteraemia
who were taking statins, particularly as the beneﬁt may not be
evident initially, but becomes apparent during longer follow up
[13]. Bloodstream infection could therefore be a surrogate
marker of risk of death from one or more other causes, or
may precipitate or deteriorate certain disease states such as
vascular disease or renal dysfunction, perhaps by the effect of
infection-related inﬂammation on the progression of athero-
sclerosis [14,15]. This may also be one of the reasons why
patients with known vascular or renal disease in our study
were at a greater risk of death over the 3-year period than
those with other co-morbidities. The other potentially inter-
TABLE 3. Predictors of 3-year mortality at the time of bacteraemia, temperature treated as a continuous variable
Variable Died by 3 years (n = 158) Survived to 3 years (n = 164) Univariate p value Cox regression p value OR (95% CI)
Age (years)a 75 63 <0.0001 <0.0001 1.034 (1.017–1.051)
IMDSa 22.02 24.63 >0.1 N/A N/A
MRSA (compared with all
other isolates)
38 (24.0) 13 (7.9) 0.0002 >0.1 N/A
Pulse (/min)a 95 91 >0.1 N/A N/A
Systolic BP (mmHg)a 123 120 >0.1 N/A N/A
Respiratory rate (/min)a 20 18 0.0063 >0.1 N/A
Temperature (°C)a 38.0 38.1 0.0389 >0.1 N/A
Creatinine (lmol/L)a 162 105 <0.0001 >0.1 N/A
Urea (mmol/L)a 12.05 6.9 <0.0001 0.044 1.023 (1.001–1.045)
Haemoglobin (g/dL)a 10.1 11.1 0.0009 >0.1 N/A
White cell count (9109)a 11.85 12.15 >0.1 N/A N/A
Albumin (g/L)a 24 27 0.0001 0.004 0.949 (0.916–0.983)
CRP (mg/L)a 165.5 166 >0.1 N/A N/A
Initial antibiotic active 130 (82.3) 133 (81.1) >0.1 N/A N/A
Vascular co-morbidity 59 (37.3) 50 (30.5) >0.1 0.05 0.635 (0.403–1.001)
Renal co-morbidity 52 (32.9) 40 (24.4) >0.1 >0.1 N/A
Respiratory co-morbidity 19 (12.0) 19 (11.6) >0.1 >0.1 N/A
Diabetic 32 (20.2) 33 (20.1) >0.1 >0.1 N/A
aValues are medians or absolute values (%).
IMDS, Index of Multiple Deprivation Score; MRSA, methicillin-resistant Staphylococcus aureus; BP, blood pressure; CRP, C-reactive protein.
FIG. 2. Kaplan–Meier survival curves of age, urea, albumin and temperature.
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esting ﬁnding from our cohort is the association between low
body temperature at the time of bacteraemia and increased
mortality at 3 years. A recent study in critical care patients
with and without sepsis, found that whereas high fever was
associated with poor short-term outcome, a moderate pyrexia
was associated with reduced mortality, and anti-pyretic
treatment was associated with a poorer outcome [16]. We
have previously noted the effect of low temperature on early
mortality in patients with pneumonia and in an early review of
this bacteraemia cohort [17], and an older study found that
patients who had experienced chills with their infection had a
reduced mortality in long-term follow-up [18]. Why this
should be associated with long-term, but not short-term,
mortality is unclear, but potentially it could be a marker of an
immune response, relating to an impaired ability to mount a
fever to subsequent infections and as a result an increased risk
of death.
Our study has several limitations. Although some data were
collected at the time of initial presentation, retrospective
supplementation was required. Additionally, as routinely
collected data were used some data were inevitably not
recorded and it is therefore possible that this may have
affected our results. We did not include a control group and
we are therefore unable to comment on mortality in a
comparable population that had not suffered bacteraemia.
Three earlier studies looking at long-term mortality after
bacteraemia, however, used either a case–control design or
compared bloodstream infection patients with those without
infection [1,2,18] and found that patients with bacteraemia had
increased mortality throughout follow up compared with the
non-bacteraemic controls. We did not collect data on cause of
death because this was not readily available, although we hope
to collect these data in a subsequent study. These data would
be necessary to fully understand the causes of death over time
and the interventions that may be of use in modifying this.
However, a recent population-based survey of 1-year mortal-
ity in patients who had community-acquired bloodstream
infections, found that 39% died of malignancy and 24% from
cardiovascular disease [3]. Because of the nature of our
service, a low percentage of patients in this cohort had
progressive haematological or other malignancy. Despite this,
mortality in the follow-up period was still considerable
suggesting that there may be an opportunity to address
vascular or other causes of mortality and morbidity, perhaps
by some form of risk-factor-based assessment of those
patients who survive the initial period after a bacteraemic
episode.
Our data, and that of other researchers, suggest that the
time for a large and detailed prospective study aimed at
understanding better the causes of mortality after bloodstream
infection is long overdue and would be useful in providing
evidence about who to follow up, the nature of the follow up
required and the opportunity for cost-effective therapeutic
intervention. In the interim, as specialist infection input has
been shown to have a beneﬁcial impact in several studies of
bloodstream infection and may improve outcomes up to
1 year after bacteraemia [19–22], it would appear sensible to
consider the appreciable and poorly recognized longer-term
mortality after an episode of bloodstream infection by
reviewing the stability of existing co-morbidities combined
with an assessment of future cardiac risk.
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